Safety, Tolerability and the Pharmacokinetics of Ridinilazole in Adolescent Subjects

PHASE3TerminatedINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

May 19, 2021

Primary Completion Date

September 17, 2021

Study Completion Date

September 28, 2022

Conditions
Clostridioides Difficile Infection
Interventions
DRUG

Ridinilazole

Ridinilazole 200mg dosed BID for 10 days.

DRUG

Vancomycin

Vancomycin 125mg dosed QID for 10 days.

Trial Locations (18)

10029

Icahn School of Medicine at Mount Sinai, New York

11758

DiGiovanna Institute for Medical Education and Research, New York

11794

Stony Brook University Medical Center, Stony Brook

30342

Children's Center for Digestive Health, Atlanta

32819

HMD Research, Orlando

33144

Continental Clinical Research, Miami

Dynamic Medical Research LLC, Miami

33155

D&H National Research Centers, Miami

44106

University Hospitals Cleveland Medical Center - Rainbow Babies and Children's Hospital, Cleveland

45229

Cincinnati Children's Hospital Medical Center, Cincinnati

46202

Indiana University Health - Riley Hospital for Children, Indianapolis

48201

Children's Hospital of Michigan, Detroit

60611

Ann and Robert H Lurie Children's Hospital of Chicago, Chicago

60637

University of Chicago - Comer Children's Hospital, Chicago

83404

Snake River Research, Idaho Falls

90095

University of California, Los Angeles (UCLA) David Geffen School of Medicine, Los Angeles

92868

Children's Hospital Orange County, Orange

02115

Boston Children's Hospital, Boston

Sponsors
All Listed Sponsors
collaborator

Department of Health and Human Services

FED

lead

Summit Therapeutics

INDUSTRY